The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
Open accessAbstract
SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile with selective inhibition of Janus Kinase-2 (JAK2; IC50=23 and 19 nM for JAK2(WT) and JAK2(V617F), respectively) within the JAK family (IC50=1280, 520 and 50 nM for JAK1, JK3 and TYK2, respectively) and fms-like tyrosine kinase-3 (FLT3; IC50=22 nM). SB1518 shows potent effects on cellular JAK/STAT pathways, inhibiting tyrosine phosphorylation on JAK2 (Y221) and downstream STATs. As a consequence SB1518 has potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis. SB1518 has favorable pharmacokinetic properties after oral dosing in mice, is well tolerated and significantly reduces splenomegaly and hepatomegaly in a JAK2(V617F)-driven disease model. SB1518 dose-dependently inhibits intra-tumor JAK2/STAT5 signaling, leading to tumor growth inhibition in a subcutaneous model generated with SET-2 cells derived from a JAK2(V617F) patient with megakaryoblastic leukemia. Moreover, SB1518 is active against primary erythroid progenitor cells sampled from patients with myeloproliferative disease. In summary, SB1518 has a unique profile and is efficacious and well tolerated in JAK2-dependent models. These favorable properties are now being confirmed in clinical studies in patients with myelofibrosis and lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Cited by
Matrigel: From discovery and ECM mimicry to assays and models for cancer research
Benton, G., Arnaoutova, I., George, J., Kleinman, H. K., & Koblinski, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.005 · Cited by 477
Macrocycles In New Drug Discovery
Mallinson, J., & Collins, I. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.93 · Cited by 468
Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction
Xu, M., Tchkonia, T., & Kirkland, J. L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.015 · Cited by 99
“Other inhibitors that target different JAKs are in clinical trials for treating myelofibrosis (22, 30), acute myeloid leukemia (31), lymphoma (32), and rheumatoid arthritis (22, 33, 34).”
Hosseini, M. M., Kurtz, S. E., Abdelhamed, S., Mahmood, S., Davare, M. A., Kaempf, A., Elferich, J., McDermott, J. E., Liu, T., Payne, S. H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0112-2 · Cited by 65
JAK-STAT Signaling in Stem Cells
Stine, R. R., & Matunis, E. L. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-6621-1_14 · Cited by 56
Metadata
- Authors
- Hart, S., Goh, K. C., Novotny-Diermayr, V, Hu, C. Y., Hentze, H., Tan, Y. C., Madan, B., Amalini, C., Loh, Y. K., Ong, L. C., William, A. D., Lee, A., Poulsen, A., Jayaraman, R., Ong, K. H., Ethirajulu, K., Dymock, B. W., & Wood, J. W.
- Venue
- Leukemia
- Published
- 2011-06-21
- Volume
- 25
- Issue
- 11
- Pages
- 1751-1759
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1973160387
- Cited by
- 200
- References
- 1
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. https://app.cochat.ai/papers/10.1038/leu.2011.148
- The paper
- Hart, S., Goh, K. C., Novotny-Diermayr, V, Hu, C. Y., Hentze, H., Tan, Y. C., Madan, B., Amalini, C., Loh, Y. K., Ong, L. C., William, A. D., Lee, A., Poulsen, A., Jayaraman, R., Ong, K. H., Ethirajulu, K., Dymock, B. W., & Wood, J. W. (2011). SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. https://doi.org/10.1038/leu.2011.148
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
